Mu opioid receptor gene polymorphism and neuroleptic-induced tardive dyskinesia in patients with schizophrenia [2]

Schizophrenia Research

Volumn 65, Issue 1, 2003, Pages 61-63

  Tan, Ene Choo ^a   Chong, Siow Ann ^b   Mahendran, Rathi ^b   Tan, Chay Hoon ^c,d   Teo, Yik Ying ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY AGENCY   (Singapore)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; MU OPIATE RECEPTOR; NEUROLEPTIC AGENT;

ANAMNESIS; BLOOD SAMPLING; CHI SQUARE DISTRIBUTION; CLINICAL FEATURE; CORRELATION COEFFICIENT; DEMOGRAPHY; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DYSKINESIA; GENE FREQUENCY; GENOTYPE; HOSPITALIZATION; HUMAN; LETTER; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MEDICAL ASSESSMENT; MOTOR DYSFUNCTION; MULTIPLE REGRESSION; NARCOLEPSY; PATHOGENESIS; PRIORITY JOURNAL; RATING SCALE; RECEPTOR BINDING; RISK FACTOR; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA; VENOUS BLOOD;

EID: 0242415455     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(02)00491-7     Document Type: Letter

References (15)

1. Practice Guidelines for the Treatment of Patients with Schizophrenia. 1997;American Psychiatric Press, Washington, DC.
2. Bailey L.G., Maxwell S., Brandabur M.M. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1027 patients. Psychopharmacol. Bull. 33:1997;177-181.
3. Bower C.M., Hyde T.M., Zaka M., Hamid E.H., Baca S.M., Egan M.F. Decreased mu-opioid receptor binding in the globus pallidus of rats treated with chronic haloperidol. Psychopharmacology (Berl.). 150:2000;260-263.
4. Dixon L., Weiden P.J., Haas G., Sweeney J., Frances A.J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr. Psychiatry. 33:1992;121-122.
5. Gelernter J., Kranzler H., Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol. Psychiatry. 4:1999;476-483.
6. Glazer W.M. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J. Clin. Psychiatry. 61(Suppl. 4):2000;15-20.
7. Guy W. Assessment manual for psychopharmacology. Publication (ADH). vol. 76-338:1976;534-537 US Dept. of Health, Education, and Welfare, Washington, DC. ECDEU.
8. Kane J.K.M., Aguglia E., Altamura C., Guiterrez J.L.A., Brunello N., Fleischhacker W.W., Gaebel W., Gerlach J., Guelfi J.D., Kissling W., Lapierre Y.D., Lindstrom E., Mendlewicz J., Racagni G., Carulla L.S., Schooler N.R. Guidelines for depot antipsychotic treatment in schizophrenia. Eur. Neuropsychopharmacol. 8:1998;55-66.
9. O'Callaghan E., Larkin C., Kinsella A., Waddington J.L. Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia. Br. J. Psychiatry. 157:1990;578-584.
10. Ohmori O., Shinkai T., Hori H., Kojima H., Nakamura J. Polymorphisms of mu and delta opioid receptor genes and tardive dyskinesia in patients with schizophrenia. Schizophr. Res. 52:2001;137-138.
11. Sasaki T., Kennedy J.L., Nobrega J.N. Autoradiographic mapping of mu opioid receptor changes in rat brain after long-term haloperidol treatment: relationship to the development of vacuous chewing movements. Psychopharmacology (Berl.). 128:1996;97-104.
12. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 39:1982;486-487.
13. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 212:1970;11-19.
14. Swofford C.D., Scheller-Gilkey G., Miller A.H., Woolwine B., Mance R. Double jeopardy: schizophrenia and substance use. Am. J. Drug Alcohol Abuse. 26:2000;343-353.
15. Waddington J.L., Youssef H.A. The expression of schizophrenia, affective disorder, and vulnerability to tardive dyskinesia in an extensive pedigree. Br. J. Psychiatry. 153:1988;376-381.